| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/02/2004 | WO2004041845A3 Templated native silk smectic gels |
| 09/02/2004 | WO2004041190A3 Composition for the treatment of macular degenration |
| 09/02/2004 | WO2004034971A9 Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| 09/02/2004 | WO2004029205A3 Structural and cytoskeleton-associated proteins |
| 09/02/2004 | WO2004024176A8 Synergistic combination of silk proteins |
| 09/02/2004 | WO2004022657A3 Increasing of the resorption of substances via skin and mucous membranes |
| 09/02/2004 | WO2004020665A3 Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
| 09/02/2004 | WO2004020596A3 Polypeptides for increasing mutant cftr channel activity |
| 09/02/2004 | WO2004015079A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/02/2004 | WO2004008102A3 Liver tumor marker sequences |
| 09/02/2004 | WO2004002421A3 Method for the treatment of multiple sclerosis |
| 09/02/2004 | WO2004001384A3 Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| 09/02/2004 | WO2003105763B1 Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
| 09/02/2004 | WO2003096981A3 Method of modulating angiogenesis |
| 09/02/2004 | WO2003087843A3 Diagnostics and therapeutics for diseases associated with mas related gene f (mrgf) |
| 09/02/2004 | WO2003087156A3 Heterogeneous crosslinked protein networks and methods for producing them |
| 09/02/2004 | WO2003086312A3 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof |
| 09/02/2004 | WO2003084344A3 Method of improving absorption of vitamin e by a pet animal |
| 09/02/2004 | WO2003063910A3 β-HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER |
| 09/02/2004 | WO2003037933A3 Dermopharmaceutically and cosmetically active oligopeptides |
| 09/02/2004 | WO2003032906A3 Delivery of poorly soluble drugs |
| 09/02/2004 | WO2003015697A3 Interleukin-2 mutants with reduced toxicity |
| 09/02/2004 | WO2003004689A3 Regulators of biofilm formation and uses thereof |
| 09/02/2004 | WO2003002717A3 Biological activity of ak155 |
| 09/02/2004 | WO2002074289A3 Antitumor compositions containing taxane derivatives |
| 09/02/2004 | US20040172687 Modified proteinase inhibitors |
| 09/02/2004 | US20040172665 Compositions and methods for treating enzyme deficiency |
| 09/02/2004 | US20040171842 VIRICIDES; uSING A SECONDARY AMIDE COMPOUNDAIDS |
| 09/02/2004 | US20040171825 Human fibroblast growth factor-related compositions |
| 09/02/2004 | US20040171816 Humanized antibodies that recognize beta amyloid peptide |
| 09/02/2004 | US20040171815 treatment of diseases associated with amyloid deposits in the brain (pre-clinical Alzheimer's disease or Down's syndrome); genetic engineering |
| 09/02/2004 | US20040171812 found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it; for determining molecular weight, isoelectric point, amino acid sequence and allergenicity; for immunoassay/therapy |
| 09/02/2004 | US20040171807 involves engineering a recombinant shuttle vector comprising a nucleic acid cassette encoding prokaryotic green fluorescent protein (GFP) operably linked to regulatory sequences which permit its expression in a host cell |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171803 Artificial protein having potentiated immunogenicity of epitope |
| 09/02/2004 | US20040171802 Haemophilus influenzae antigens and corresponding dna fragments |
| 09/02/2004 | US20040171800 Gamma retinoic acid receptor |
| 09/02/2004 | US20040171796 comprising an agonist of a majort histocompatability complex (MHC) class I binding native sequence having enhanced immunogenicity; for inhibiting or killing CEA epitope-expressing carcinoma cells; genetic engineering; kits |
| 09/02/2004 | US20040171794 Kunitz domain peptides |
| 09/02/2004 | US20040171793 Cyclic peptides as potent and selective melanocortin-4 receptors agonists |
| 09/02/2004 | US20040171695 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 09/02/2004 | US20040171690 Use of protein essential aminoacids to treat amenorrhea and related disorders |
| 09/02/2004 | US20040171689 Screening method using solid supports modified with self-assembled monolayers |
| 09/02/2004 | US20040171678 Reduced toxicity; blocking p-glycoprotein membrane toxin extrusion pump |
| 09/02/2004 | US20040171669 Rapid disintegration on contact with saliva forming easy to swallow palatable suspension; tablets |
| 09/02/2004 | US20040171660 Single dose aromatase inhibitor for treating infertility |
| 09/02/2004 | US20040171575 Antisense modulation of interferon gamma receptor 2 expression |
| 09/02/2004 | US20040171574 Growth hormone and growth hormone releasing hormone compositions |
| 09/02/2004 | US20040171569 that directs formation of a recombinant virus upon introduction into a cell |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171567 Method for detection of neoplastic cells |
| 09/02/2004 | US20040171566 in a formulation suitable for intranasal, intrapulmonary or intratracheal administration; treating inflammatory diseases, particularly rheumatoid arthritis and asthma |
| 09/02/2004 | US20040171564 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression |
| 09/02/2004 | US20040171563 Novel use of tyrosine kinase inhibitor |
| 09/02/2004 | US20040171562 covalently forming prodrug by linking oligopeptide cleavable by plasmin to a stabilizing group and directly or indirectly linking the therapeutic agent at a second attachment site to oligopeptide; decreasing the toxicity of a therapeutic agent |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171556 Methods for inhibiting proteasome |
| 09/02/2004 | US20040171555 inhibitors of dipeptidyl peptidase; treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae of diabetes mellitus in mammals |
| 09/02/2004 | US20040171554 Compositions and methods for enhancing apoptosis |
| 09/02/2004 | US20040171553 Peptides fragments of colostrinin and their use |
| 09/02/2004 | US20040171552 for treating a condition involving abnormal cell migration in a subject |
| 09/02/2004 | US20040171551 which binds to an amino acid sequence comprising at least 5 EP motifs over a 19 amino acid segment |
| 09/02/2004 | US20040171550 inhalation of the powder from an inhaler device which dispenses the correct dose of powdered polypeptide/enhancer in a particle size which maximizes deposition in the lower respiratory tract |
| 09/02/2004 | US20040171549 Method of inhibiting angiogenesis or invasion or formation of metastases |
| 09/02/2004 | US20040171548 Method of treatment of conditions by administration of streptolysin O |
| 09/02/2004 | US20040171547 inhibiting the growth of a cancerous cell by contacting cell with an effective amount of a RhoB protein, or a variant of the RhoB protein; alone or in combination with additional anti-cancer agents, such as cytotoxic agents (e.g., 5-flurouracil) |
| 09/02/2004 | US20040171546 Regulation of lung tissue by hedgehog-like polypeptides and formulations and uses related thereto |
| 09/02/2004 | US20040171544 treating or preventing epithelial lesions in a mammal (e.g., a human) using trefoil domain-containing polypeptides |
| 09/02/2004 | US20040171542 T1249 is a member of a new class of antiviral agents that inhibit virus/membrane fusion |
| 09/02/2004 | US20040171541 combination comprising a polypeptide comprising the modulating sequence of the erythropoietin receptor and a non-peptide organic molecule in the treatment of anemia |
| 09/02/2004 | US20040171540 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr protein, and uses thereof |
| 09/02/2004 | US20040171539 Regulation of human protein kinase-like protein |
| 09/02/2004 | US20040171538 Anticoagulants and their uses |
| 09/02/2004 | US20040171537 Adapter gene |
| 09/02/2004 | US20040171536 human immunodeficiency virus inhibiting protein (HIVIP) isolated from poisonous snake Australian taipan |
| 09/02/2004 | US20040171535 Heparanase II, a novel human heparanase paralog |
| 09/02/2004 | US20040171534 chimeric analogs include a hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF |
| 09/02/2004 | US20040171533 Methods and compositions for regulating adiopocytes |
| 09/02/2004 | US20040171532 coadministering a taxane and an oral bioavailability enhancing agent inhibitor of p-glycoprotein; preventing or reducing hypersensitivity or allergic reactions; anticancer agents |
| 09/02/2004 | US20040171531 Non-aqueous injectable formulations for extended release of somatotropin |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171529 Treatment with neurotrophic factors |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171525 Administering lectin being effective to diminish infective capability of microorganism |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171521 Non-aqueous surfactant-containing formulations for extended release of somatotropin |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171519 Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria |
| 09/02/2004 | US20040171518 Compounds for protein stabilization and methods for their use |
| 09/02/2004 | US20040171517 Compounds and methods for modulating bacterial functions |
| 09/02/2004 | US20040171159 Cell-specific adenovirus vector comprising EBV-specific promoter |
| 09/02/2004 | US20040171155 Materials and methods for management of hyperacute rejection in human xenotransplantation |
| 09/02/2004 | US20040171149 Oligonucleotides for controlling growth factor expression and treatment of cell proliferative and skin disorders; antisense agents |
| 09/02/2004 | US20040171131 Nucleotide sequences coding enzymatic polypeptide associated with tubulin tyrosination for diagnosing, preventing and treating cell proliferative, gastrointestinal and reproductive disorders; antitumor agents |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171122 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 09/02/2004 | US20040171117 Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders |
| 09/02/2004 | US20040171116 Recombinant protein variants |